Compare · LLY vs NTHI
LLY vs NTHI
Side-by-side comparison of Eli Lilly and Company (LLY) and NeOnc Technologies Holdings Inc. (NTHI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NTHI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $883.03B, about 8019.6x NTHI ($110.1M).
- Over the past year, LLY is up 17.8% and NTHI is down 17.5% - LLY leads by 35.3 points.
- NTHI has been more active in the news (19 items in the past 4 weeks vs 14 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 1 for NTHI).
- Company
- Eli Lilly and Company
- NeOnc Technologies Holdings Inc.
- Price
- $934.86+9.79%
- $4.37+6.59%
- Market cap
- $883.03B
- $110.1M
- 1M return
- +1.65%
- -37.64%
- 1Y return
- +17.77%
- -17.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 19
- Recent ratings
- 25
- 1
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- SEC Form 10-Q filed by Eli Lilly and Company
- Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
- Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 4 filed by Sulzberger Gabrielle
- SEC Form 4 filed by Luciano Juan R
- SEC Form 4 filed by Fyrwald J Erik
- SEC Form 4 filed by Alvarez Ralph
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Latest NTHI
- President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)
- Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)
- CFO Garnett Keithly bought $1,614 worth of shares (300 units at $5.38), increasing direct ownership by 0.12% to 241,200 units (SEC Form 4)
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- BTIG Research initiated coverage on NeOnc Technologies Holdings with a new price target
- President Heshmatpour Amir F bought $49,000 worth of shares (10,000 units at $4.90), increasing direct ownership by 0.33% to 3,052,000 units (SEC Form 4)
- SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.
- NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results